# AIDX (20/20 Biolabs, Inc.) - SEC EDGAR Financial Statements

> 20/20 Biolabs, Inc. reported $2.00M in revenue and a net loss of $6.36M for the trailing twelve months ended September 30, 2026 (down 9.0% year over year), with a 29.7% gross margin and a -249.2% operating margin.

- Canonical: https://convexityos.com/fundamentals/AIDX
- Markdown: https://convexityos.com/fundamentals/AIDX.md
- SEC CIK: 0001139685
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:11 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001139685&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | TTM | $2.00M | -9.0% YoY |
| Operating Income | TTM | -$4.99M | -249.2% margin |
| Net Income | TTM | -$6.36M | -317.8% net margin |
| Diluted EPS | TTM | -$0.49 | Split-adjusted |
| Free Cash Flow | TTM | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $3.63M | Total debt: $526K |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| **Revenue** | $2.05M | $1.75M |
| Cost of Revenue | $1.44M | $1.39M |
| **Gross Profit** | $605K | $360K |
| Research & Development | $593K | $1.26M |
| Selling, General & Admin | $3.34M | $4.76M |
| Total Operating Expenses | $3.94M | $6.04M |
| **Operating Income** | -$3.33M | -$5.68M |
| **EBITDA** | -$3.27M | -$5.56M |
| Interest Income | $21K | $79K |
| Interest Expense | $156K | $13K |
| **Net Income** | -$3.74M | -$5.55M |
| Basic EPS | -$0.76 | -$1.16 |
| **Diluted EPS** | -$0.76 | -$1.16 |
| Basic Shares Outstanding | 4.9M | 4.8M |
| Diluted Shares Outstanding | 4.9M | 4.8M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $380K | $731K | $353K | $538K | $418K | $535K | $554K |
| Cost of Revenue | $283K | $426K | $290K | $408K | $273K | $372K | $388K |
| **Gross Profit** | $97K | $305K | $63K | $130K | $145K | $163K | $166K |
| Research & Development | $123K | $258K | $153K | $131K | $131K | $194K | $137K |
| Selling, General & Admin | $1.36M | $1.29M | $1.35M | $913K | $814K | $815K | $801K |
| Total Operating Expenses | $1.49M | $1.55M | $1.51M | $1.04M | $945K | $1.01M | $938K |
| **Operating Income** | -$1.39M | -$1.24M | -$1.44M | -$913K | -$800K | -$846K | -$772K |
| **EBITDA** | -$1.38M | -$1.23M | -$1.43M | -$898K | -$785K | -$830K | -$754K |
| Interest Income | $15K | $14K | $6.7K | $3.1K | $4.2K | $5.7K | $8.5K |
| Interest Expense | -$1 | $272K | $267K | $125K | $30K | $935 | $740 |
| **Net Income** | -$1.38M | -$1.51M | -$2.17M | -$1.31M | -$826K | -$841K | -$765K |
| Basic EPS | -$0.12 | -$0.26 | -$0.28 | -- | -$0.17 | -$0.17 | -$0.16 |
| **Diluted EPS** | -$0.12 | -$0.26 | -$0.28 | -- | -$0.17 | -$0.17 | -$0.16 |
| Basic Shares Outstanding | 13.0M | 10.8M | 7.7M | -- | 4.8M | 4.8M | 4.8M |
| Diluted Shares Outstanding | 13.0M | 10.8M | 7.7M | -- | 4.8M | 4.8M | 4.8M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Cash & Cash Equivalents | $1.03M | $1.78M |
| **Cash & Short-Term Investments** | $1.03M | $1.78M |
| Accounts Receivable, Net | $200K | $135K |
| Inventory | $116K | $47K |
| **Total Current Assets** | $1.47M | $2.03M |
| Property, Plant & Equipment, Net | $57K | $117K |
| Intangible Assets | $202K | $206K |
| Other Non-Current Assets | $23K | $162K |
| **Total Non-Current Assets** | $2.67M | $1.55M |
| **Total Assets** | $4.14M | $3.58M |
| Accounts Payable | $869K | $372K |
| Deferred Revenue (Current) | $415K | $470K |
| **Total Current Liabilities** | $2.46M | $1.36M |
| Deferred Revenue (Non-Current) | $42K | $50K |
| **Total Non-Current Liabilities** | $1.69M | $724K |
| **Total Liabilities** | $4.16M | $2.08M |
| **Total Debt (incl. Leases)** | $665K | $840K |
| Common Stock | $54K | $48K |
| Retained Earnings | -$33.25M | -$29.51M |
| **Total Stockholders' Equity** | -$19K | $1.51M |
| Total Equity | -$19K | $1.51M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $3.63M | $4.55M | $4.22M | $1.03M | $1.78M |
| **Cash & Short-Term Investments** | $3.63M | $4.55M | $4.22M | $1.03M | $1.78M |
| Accounts Receivable, Net | $174K | $291K | $201K | $200K | $135K |
| Inventory | $103K | $111K | $105K | $116K | $47K |
| **Total Current Assets** | $4.03M | $5.08M | $4.70M | $1.47M | $2.03M |
| Property, Plant & Equipment, Net | $25K | $34K | $45K | $57K | $117K |
| Intangible Assets | $205K | $206K | $207K | $202K | $206K |
| Other Non-Current Assets | $23K | $23K | $23K | $23K | $162K |
| **Total Non-Current Assets** | $988K | $1.05M | $1.10M | $2.67M | $1.55M |
| **Total Assets** | $5.02M | $6.12M | $5.80M | $4.14M | $3.58M |
| Accounts Payable | $1.05M | $1.03M | $980K | $869K | $372K |
| Deferred Revenue (Current) | $479K | $467K | $451K | $415K | $470K |
| **Total Current Liabilities** | $2.49M | $2.55M | $2.58M | $2.46M | $1.36M |
| Deferred Revenue (Non-Current) | $29K | $33K | $37K | $42K | $50K |
| **Total Non-Current Liabilities** | $359K | $413K | $466K | $1.69M | $724K |
| **Total Liabilities** | $2.85M | $2.96M | $3.05M | $4.16M | $2.08M |
| **Total Debt (incl. Leases)** | $526K | $572K | $619K | $665K | $840K |
| Common Stock | $134K | $123K | $104K | $54K | $48K |
| Retained Earnings | -$38.30M | -$36.93M | -$35.42M | -$33.25M | -$29.51M |
| **Total Stockholders' Equity** | $611K | $1.62M | $2.55M | -$19K | $1.51M |
| Total Equity | $611K | $1.62M | $2.55M | -$19K | $1.51M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Net Income | -$3.74M | -$5.55M |
| Depreciation & Amortization | $63K | $116K |
| Stock-Based Compensation | $516K | $2.18M |
| Change in Receivables | -$65K | -$66K |
| Change in Inventory | -$69K | $14K |
| Change in Payables | $496K | $12K |
| **Operating Cash Flow** | -$1.92M | -$2.60M |
| **Financing Cash Flow** | $1.16M | $293K |
| **Net Change in Cash** | -$758K | -$2.31M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$1.38M | -$1.51M | -$2.17M | -$1.31M | -$826K | -$841K | -$765K |
| Depreciation & Amortization | $10.0K | $12K | $12K | $15K | $15K | $15K | $18K |
| Stock-Based Compensation | $210K | $371K | $128K | $127K | $130K | $130K | $130K |
| Change in Receivables | $118K | -$90K | -$1.5K | -$63K | $37K | -$45K | $5.6K |
| Change in Inventory | $8.5K | -$6.5K | $12K | -$61K | $6.9K | $6.4K | -$21K |
| Change in Payables | $97K | $46K | $112K | $240K | $72K | $73K | $111K |
| **Operating Cash Flow** | -$912K | -$605K | -$1.29M | -$512K | -$386K | -$534K | -$488K |
| **Investing Cash Flow** | $0 | -$7.5K | -$5.4K | -- | -- | -- | -- |
| **Financing Cash Flow** | $0 | $940K | $4.49M | $393K | $507K | $0 | $262K |
| **Net Change in Cash** | -$912K | $327K | $3.19M | -$119K | $121K | -$534K | -$226K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| **Gross Margin** | 29.6% | 20.6% |
| **Operating Margin** | -162.9% | -324.0% |
| **Net Profit Margin** | -182.8% | -316.8% |
| Return on Equity (ROE) | -- | -368.8% |
| Return on Assets (ROA) | -90.4% | -154.9% |
| Current Ratio | 0.60x | 1.50x |
| Quick Ratio | 0.55x | 1.47x |
| Debt to Equity | -- | 0.56x |
| **Revenue Growth (YoY)** | +16.7% | -- |
| Gross Profit Growth (YoY) | +67.8% | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Gross Margin** | 29.7% | 31.5% | 27.2% | 29.6% | -- | -- | -- |
| **Operating Margin** | -249.2% | -215.7% | -216.9% | -162.9% | -- | -- | -- |
| **Net Profit Margin** | -317.8% | -285.0% | -279.1% | -182.8% | -- | -- | -- |
| Return on Equity (ROE) | -1041.2% | -358.8% | -201.7% | -- | -- | -- | -- |
| Return on Assets (ROA) | -126.8% | -95.0% | -88.7% | -90.4% | -- | -- | -- |
| Current Ratio | 1.62x | 1.99x | 1.82x | 0.60x | -- | -- | -- |
| Quick Ratio | 1.58x | 1.95x | 1.78x | 0.55x | -- | -- | -- |
| Debt to Equity | 0.86x | 0.35x | 0.24x | -- | -- | -- | -- |
| **Revenue Growth (YoY)** | -9.0% | +36.5% | -36.2% | -- | -- | -- | -- |
| Gross Profit Growth (YoY) | -33.2% | +86.6% | -62.1% | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
